SREK1IP1

Across TCGA pan-cancer cohorts, SREK1IP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SREK1IP1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SREK1IP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SREK1IP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SREK1IP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.320	0.587	.009	19	view →
CCRCC	DFS	Median	All	0.577	0.854	.013	8	view →
LUAD	DFS	Median	III,IV	0.432	1.000	.024	3	view →
UCEC	DFS	Tertile	All	0.929	0.717	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SREK1IP1–PDAC (DFS)

Open the PDAC breakdown →